Introduction section
4. It is said, in the Introduction section, that, "To address this, an update to existing pharmacovigilance legislation was initiated…". One can (or wants to) think that things are like this, but there is no evidence that legislation initiatives are taken in this manner. What you mention -elevated death toll due to ADRs, etcetera-is the context, but which triggers such initiatives is the results of many circumstances. I rather suggest, "in this context, an initiative..." 5. Instead of "a major aim of these legislations". The legislation themselves do not have any aim, may be the legislator; even so, and to be precise, it should be better state, "the declared aim…" and then to insert the explicit aim in the legislation with quotation marks. As an investigator you need to adopt a certain distance.
6. Regarding the objectives of the study, more than "the strength of evidence", it would be "the source of evidence" or "the type of evidence"; in fact, these terms are used in other parts of the manuscript. Case reports as a method may be regarded as a lowlevel evidence in a scale of evidences; but for a particular signal assessment, it cannot be regarded as a weak evidence a large case series with much information and in which all or the majority of cases have a positive re-challenge. Method 7. It is stated that, "Prescription medications withdrawn from market in the EU for safety reasons…. plus Norway, Lichtenstein, and Iceland". By reading the manuscript, it is not always clear the geographical location to be studied. Neither the type of regulatory measure adopted: only withdrawals, as above ("Prescription medications withdrawn from market."), or withdrawals, suspensions and revocations as it seems to be the case.
8. Note that including revoked or suspended indications, for instance, may account for non-comparability with other studies addressing the same topic.
9. It is said that only a "… response was received for one product which was assessed for fulfilment of inclusion criteria". It does not seem too much; it should be explained in the Discussion section.
10. It is stated that, the "strength of publically available evidence contributing to the benefit-risk evaluation thus supporting the withdrawal, revocation, or suspension was assessed" In my opinion, that cannot be reasonably known. It requires and in-depth assessment of all available information. Only the type of sources or evidences are presented in this study.
Results
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. It is said that, "Eighteen active substances withdrawn, suspended, or revoked within the EU between 01 July 2012 and 31 December 2016 met the inclusion criteria". But also that, "All prescription products withdrawn, revoked, or suspended for safety reasons across all EU Member States in addition to those that underwent pharmacovigilance action in a single Member State during the time period 01 July 2012 to 31 December 2016 were included".
While "eighteen active substances" (INN) is repeatedly mentioned it is not the same with the other 5 substances ("Two additional products underwent regulatory action solely in Germany, two in the United Kingdom, and one was suspended in France); according to the stated inclusion criteria the figure would be "twenty-three". These additional products should be included in the table and discussed accordingly. Also, in another column, times to reach a regulatory decision, should be included. Discussion 12. When reading "more robust sources" it is probably understood that one type of sources (of information) is better than other; in this way, you are dismissing the supposedly low-level evidence sources. A priori, and for regulatory activities, none of the sources is better than other; it will depend on the problem. In practice, they complement each other.
13. A statistics analysis would be advisable for the times taken to reach the regulatory decision. Was it statistically different from the beginning to the end of the period considered? Accordingly, a discussion of this changes is necessary. By reading the manuscript it is not clear whether things are better now.
14. Finally, there is not any explanation of why only products with long periods in the market are regulated; it should be clearly discussed. What is the role of the "risks management plans" for new products them not appearing in these types of regulations. The authors attempt to explore trends in the post-marketing withdrawal of medicinal products in Europe following the EU 2010/84/ directive. The topic is of interest, and gaining an insight into the present trends would be helpful to drug regulators, manufacturers, and healthcare providers and the general public. However, there are several flaws in this research that need to be addressed by the authors.
MAJOR
The main purpose of the study is unclear from the introduction. First there is a "hypothesis"; then "initiation"; then "objectives". A clear rationale for why the authors decided to embark on this study needs to be described in a logical manner.
Response: Thank you for this comment. Although the importance of this work was implied throughout the introduction, we appreciate that this was not explicitly stated. We have therefore changed the structure of the introduction and added a paragraph between the introductory information and objectives paragraphs to provide a rationale.
Comment: The authors fail to pre-specify methods used to analyse the data; however, means, medians, frequencies and 95% CIs are reported in the results. The authors should also need to justify why they have included mediation error as an adverse reaction (how does this result in unfavourable benefit-harm balance?). It is also unclear who did what in the methods section.
Response: Many thanks for highlighting that pre-specification of data analysis had been omitted; the methods section now contains a data analysis subsection, and a statement of the roles of each author during data acquisition, analysis and interpretation. This is also covered in the contributorship statement at the end of the document.
The second part of your comment is most thought-provoking. In EU pharmacovigilance regulations, medication error and maladministration are included in the definition of an ADR and considered a risk factor for ADRs. The definition in GVP Annex I states adverse reactions may arise from use of the product within or outside the terms of marketing, or occupational exposure. We agree that medication error is not itself an ADR, rather it fits into the use of a medication outside the terms of marketing. However in some cases medicinal products have been withdrawn from markets when risk minimisation measures have failed to reduce the detrimental public health impact. This point has been taken into consideration, and as a result the medicinal products citing 'medication error,' 'misuse,' or 'accidental overdose' in this study have been re-evaluated. Due to the importance of these points and the trends seen in the data in comparison to the existing literature, where these terms have been cited in this manuscript they have been retained. However the resultant ADR associated with the use of the medicinal products in this way have also been included. Consequently the results and discussion sections have been amended accordingly.
I am uncertain about the use of cross-sectional studies for establishing drug-ADR association: Methadone with HMW povidone was withdrawn based on spontaneous ADRs (see http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/07/news_detail_0 02144.jsp&mid=WC0b01ac058004d5c1). Similarly, Ephedrine Hydrochloride, Lidocaine and Arsenous Anhydride withdrawal was based on genotoxicity studies (these are marketed as Caustinerf arsenical® and Yranicid arsenical®, but the authors report them as 1 product). The authors should clarify the use of cross-sectional studies for these "two" withdrawn products. Regulatory reviews (reported in regulatory documentation such as PRAC Assessment Reports) evaluated the evidence in its entirety to consider the benefit-risk balance of each individual or combination of medicinal products, leading to a conclusion on whether the medicinal product should remain on the market or face withdrawal, revocation, or suspension. The cited studies raised concerns regarding the drug's safety relative to the cited ADR. As can be seen in Table III , crosssectional studies were cited in the regulatory documentation as contributing to the decision, however no additional cross-sectional studies were identified in the published literature.
In the press release for the suspension of Methadone with HMW povidone, to which the reviewer kindly provided a link, it is stated that during its review the PRAC assessed all available safety data relating to the drug's misuse, including post-marketing ADR reports, published scientific literature, and expert opinion. Therefore although spontaneous ADR reports had a vital role in coming to the decision to suspend the marketing authorisation of this drug, additional evidence was also considered. A similar situation occurred with the two ephedrine hydrochloride, lidocaine and arsenous anhydride products, where many studies contributing to the decision were indeed in vitro genotoxicity studies, however it was stated in the EMA's Scientific Conclusions document that "In its assessment the CHMP considered all available data submitted by the MAHs as well as published literature and data available to the Member States." [Please see: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/CaustinerfYranicid/WC500170900.pdf]. Each study cited in the regulatory reports was sourced online and classified according to study design. In the cases of methadone with HMW povidone, and ephedrine hydrochloride, lidocaine and arsenous anhydride, cross-sectional study designs contributed to the benefit-risk evaluation and thus the overall decision to suspend and revoke their marketing authorisations, respectively.
The discussion requires major revisions; the authors should consider using subheadings to discuss the issues addressed. There are several repetitions of the results in this section and it makes the reading tedious. Though the authors report several comparisons with existing literature, the structure used to make the comparisons are incoherent. The strengths and limitations appear to merge with the future implications and conclusion sections.
We appreciate the comment on the structure and content of our discussion. We are in agreement that these changes have strengthened the manuscript. Therefore we have removed repeated data where appropriate and inserted subheadings to structure the text, which has improved the ability to compare to previous data coherently. We have also ensured that the strengths and limitations subsection remains separate from the conclusions and future research subsection. Furthermore, the first paragraph of the discussion section now consists of the "headline" results.
The authors use the term "retrospective study" in the abstract. This is misleading for this type of research, and this term appears nowhere else in the entire manuscript. This study looks more like a literature review.
Thank you for highlighting your concerns. We are in agreement that "retrospective study" was not the best description of our study design. This has now been amended to "an investigation" to indicate study setting in the title and abstract.
There is inconsistency with the use of terms throughout the paper: e.g. "medicinal products" versus "active substances"; "pharmacovigilance action" versus "regulatory action" versus "withdrawal"; "effect" versus "event", etc. Or they should define what each of the terms mean and whether they can be used interchangeably. We appreciate your comment. We have now ensured consistency in the terms used throughout the manuscript. We have used "medicinal product" in almost all cases, however the use of "product" has been retained when discussing other literature that described drugs included in their research using this term. "Pharmacovigilance action" has been changed to "regulatory action" in all cases, with a definition of this in both the introduction and abstract. "Adverse effect" has now been amended to read "adverse event" in all cases.
Response: Thank you for addressing this. The procedural start date may have been prior to July 2012, as we were interested in the regulatory decisions ongoing throughout the study period if the final decision was made prior to 31 December 2016. The highlighted sentence in the main text has been amended to state the product and procedural start date of both products mentioned.
A sentence has also been included in the methods to inform that procedural start date may have occurred prior to July 2012, and that products were included when the regulatory decision was made during the 2012-2016 study period.
Both means and medians are used as measures of central dispersion in the results. However, the authors do not provide any reasons for using these statistical measures. Generally, means are used for normal distribution and median for skewed data.
Mean values and their 95% confidence intervals have been removed as medians with interquartile ranges are the more appropriate measures for our data. We now also include a justification and prespecify data analysis techniques in the methods. I cannot locate Figures 1 and 2 anywhere.
These figures were submitted separately to the main text. They have been re-uploaded with this resubmission.
Discussion
The first few sentences should summarize the main results. The authors appear to premature compare their results with existing research here.
Response: Thank you for this comment. The headline results have now been inserted at the beginning of the discussion section.
Page 11, Lines 5-6: should it not be "most common source" rather than "an important source"
Response: Thank you, this has been amended.
Page 12, Lines 3-10: it is quite premature to make this conclusion because the number of withdrawn products studied is too small, and the time interval studied too short.
Response: We have acknowledged your comment and amended the text in accordance. This has also informed a potential area for future study.
Reviewer: 2 Reviewer Name: Alfonso Carvajal Institution and Country: Universidad de Valladolid (Spain) Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Overall Comment: It is not clear when you are referring to reporting systems, case reports, spontaneous ADR reports or published case reports.
Response: Thank you for this comment. We have referred to spontaneously reported and published case reports as "case reports" in the manuscript. Where appropriate this has been amended to specify that this means spontaneous ADR reports and published case reports.
Comment: For the study, a description (or definition) of what is withdrawal, suspension or revocation is needed. In addition, and related to that, you compare the results of this study addressing withdrawal, suspension or revocation with others studies that may be do not contemplate the same outcomes (only withdrawals?).
Response: No definition for any of these terms is available in EMA or GVP documentation. Nonetheless a definition of what we perceive to be meant by each of these terms has been included in the methods section.
We appreciate your comment about comparison to studies that investigate only withdrawal; we were investigating regulatory actions in terms of withdrawal, suspension and revocation of marketing authorisations however there were no previous studies identified that also looked at revocation and suspension in addition to withdrawal. During our study period there was a small number of withdrawals, therefore it was necessary to extend this to also include suspensions and revocation of marketing authorisation. We have assumed that the evidence sources used within each review would not have changed regardless of the outcome. We have now added a statement to the limitations section explaining this.
Along the manuscript, the terms "medicines", "substances" and "products" are used. While the term substance (chemical entity) is clear, particularly when it is referred as an "active substance" (this term is also used), the terms "medicines" and "products" should be clarified; maybe it is worth to use only one term. In the study by Onakpoya et al., "medicinal product" is used.
We are in agreement that continuity was needed throughout the manuscript, therefore we have now changed all to read "medicinal product" where appropriate. We based this decision on GVP Annex I definition and continuity with previous literature.
Introduction section It is said, in the Introduction section, that, "To address this, an update to existing pharmacovigilance legislation was initiated…". One can (or wants to) think that things are like this, but there is no evidence that legislation initiatives are taken in this manner. What you mention -elevated death toll due to ADRs, etcetera-is the context, but which triggers such initiatives is the results of many circumstances. I rather suggest, "in this context, an initiative..."
Response: Thank you for this comment. We are in agreement that this the proposed text is less presumptive and in fact reads better. This has therefore been amended in the manuscript.
Comment: Instead of "a major aim of these legislations". The legislation themselves do not have any aim, may be the legislator; even so, and to be precise, it should be better state, "the declared aim…" and then to insert the explicit aim in the legislation with quotation marks. As an investigator you need to adopt a certain distance.
Response: This is a very fair comment, which has been considered and accepted. We have made the suggested change to the manuscript.
Comment: Regarding the objectives of the study, more than "the strength of evidence", it would be "the source of evidence" or "the type of evidence"; in fact, these terms are used in other parts of the manuscript. Case reports as a method may be regarded as a low-level evidence in a scale of evidences; but for a particular signal assessment, it cannot be regarded as a weak evidence a large case series with much information and in which all or the majority of cases have a positive rechallenge.
Response: Many thanks for bringing this to our attention. The text reading "strength of evidence" has been amended to "source(s) of evidence."
Method It is stated that, "Prescription medications withdrawn from market in the EU for safety reasons…. plus Norway, Lichtenstein, and Iceland". By reading the manuscript, it is not always clear the geographical location to be studied. Neither the type of regulatory measure adopted: only withdrawals, as above ("Prescription medications withdrawn from market."), or withdrawals, suspensions and revocations as it seems to be the case.
Response: Thank you for highlighting this; the first sentence of the methods section has now been amended to make these points clear.
Comment: Note that including revoked or suspended indications, for instance, may account for noncomparability with other studies addressing the same topic.
Response: This has now been acknowledged in the limitations section.
Comment: It is said that only a "… response was received for one product which was assessed for fulfilment of inclusion criteria". It does not seem too much; it should be explained in the Discussion section.
Response: While we appreciate your comment, this has in fact been described in the results section, in the sentence reading "A response was obtained from the Portuguese authority, Infarmed, indicating that Diclofenac Sodium (Painex®) products were suspended following the MAH's non-submission of relevant variations to product information following a PRAC review in 2013." This has now also been mentioned in the Results section. Due to using the received data only to assess inclusion eligibility of Diclofenac Sodium, we felt it was not appropriate to analyse this in the discussion.
Comment: It is stated that, the "strength of publically available evidence contributing to the benefit-risk evaluation thus supporting the withdrawal, revocation, or suspension was assessed" In my opinion, that cannot be reasonably known. It requires and in-depth assessment of all available information. Only the type of sources or evidences are presented in this study.
Response: Many thanks, this has been addressed as a result of a previous comment. We have amended all reference to "strength of evidence" to "source(s) of evidence."
Results It is said that, "Eighteen active substances withdrawn, suspended, or revoked within the EU between 01 July 2012 and 31 December 2016 met the inclusion criteria". But also that, "All prescription products withdrawn, revoked, or suspended for safety reasons across all EU Member States in addition to those that underwent pharmacovigilance action in a single Member State during the time period 01 July 2012 to 31 December 2016 were included". While "eighteen active substances" (INN) is repeatedly mentioned it is not the same with the other 5 substances ("Two additional products underwent regulatory action solely in Germany, two in the United Kingdom, and one was suspended in France); according to the stated inclusion criteria the figure would be "twenty-three". These additional products should be included in the table and discussed accordingly. Also, in another column, times to reach a regulatory decision, should be included.
Response: We appreciate your comment. While you are correct that 23 products underwent withdrawal, suspension or revocation in the EU during the study period, only 18 were known to meet the inclusion criteria. It has been decided therefore to keep the analyses as they are and a comment has been added to the methods to explain why these medicinal products were excluded from analyses.
Based on your recommendation we have included an additional column to Table II to display the data for time to reach regulatory decision, in days. This data is also presented graphically in Figure I .
When reading "more robust sources" it is probably understood that one type of sources (of information) is better than other; in this way, you are dismissing the supposedly low-level evidence sources. A priori, and for regulatory activities, none of the sources is better than other; it will depend on the problem. In practice, they complement each other.
Response: Thank you for this comment. We are in agreement that the types of evidence perceived as "strong" or "robust" will vary based on many individual factors. We have added this concept to the limitations section.
Comment: A statistics analysis would be advisable for the times taken to reach the regulatory decision. Was it statistically different from the beginning to the end of the period considered? Accordingly, a discussion of this changes is necessary. By reading the manuscript it is not clear whether things are better now.
Response: Thank you for your suggestion. An analysis of variance has been performed to determine any difference between the times to reach a regulatory decision, grouped by year. This provided a statistic of p=0.8711, therefore while there was a small decrease in time to reach a regulatory decision there was no statistical difference found. This has been discussed accordingly.
Comment: Finally, there is not any explanation of why only products with long periods in the market are regulated; it should be clearly discussed. What is the role of the "risks management plans" for new products them not appearing in these types of regulations.
